Get the Stockscreener App
2.5709
1.89%
-0.0691
Acelyrin Inc stock is traded at $2.5709, with a volume of 76,417.
It is down -1.89% in the last 24 hours and up +0.78% over the past month.
Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of of transformative medicines.
See More
Previous Close:
$2.64
Open:
$2.64
24h Volume:
76,417
Relative Volume:
0.04
Market Cap:
$265.87M
Revenue:
-
Net Income/Loss:
$-299.80M
P/E Ratio:
-0.9052
EPS:
-2.84
Net Cash Flow:
$-217.49M
1W Performance:
-8.16%
1M Performance:
+0.78%
6M Performance:
-45.82%
1Y Performance:
-61.57%
1-Day Range:
$2.555
$2.65
1-Week Range:
$2.555
$2.855
52-Week Range:
$1.845
$7.25
Acelyrin Inc Stock (SLRN) Company Profile
Name
Acelyrin Inc
Sector
Industry
Phone
805-456-4393
Address
4149 LIBERTY CANYON RD., AGOURA HILLS
Compare SLRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLRN
Acelyrin Inc
|
2.575 | 265.87M | 0 | -299.80M | -217.49M | -2.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
508.19 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.26 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
287.50 | 37.63B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ARGX
Argen X Se Adr
|
608.33 | 37.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ONC
Beigene Ltd Adr
|
254.81 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Acelyrin Inc Stock (SLRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-08-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-08-23 | Initiated | Citigroup | Neutral |
| Sep-13-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-05-23 | Initiated | H.C. Wainwright | Buy |
| May-30-23 | Initiated | Jefferies | Buy |
| May-30-23 | Initiated | Morgan Stanley | Overweight |
| May-30-23 | Initiated | Piper Sandler | Overweight |
| May-30-23 | Initiated | TD Cowen | Outperform |
View All
Acelyrin Inc Stock (SLRN) Latest News
Acelyrin Sees Stock Price Rise Amid Rights Plan - Los Angeles Business Journal
TANG CAPITAL MANAGEMENT LLC Increases Stake in Acelyrin Inc - GuruFocus.com
ACELYRIN Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Insider Stock Sales Shake Up ACELYRIN, INC. - TipRanks
Acelyrin’s chief legal officer Murugan Amar sells $10,737 in stock By Investing.com - Investing.com South Africa
Acelyrin CEO Kim Mina sells $49,353 in company stock By Investing.com - Investing.com Australia
Acelyrin chief medical officer Mpofu Shephard sells $8,810 in stock - Investing.com
Acelyrin’s chief legal officer Murugan Amar sells $10,737 in stock - Investing.com
ACELYRIN Executives Sell Shares to Cover Tax Obligations - TradingView
Acelyrin chief medical officer Mpofu Shephard sells $8,810 in stock By Investing.com - Investing.com Australia
ALUMIS INC. SEC 10-K Report - TradingView
Alumis Inc. Reports Phase 2 and Phase 1 Clinical Data, Announces Merger Agreement with ACELYRIN, and Highlights 2024 Financial Results - Nasdaq
Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements - The Manila Times
Alumis Doubles R&D Investment, Secures Game-Changing Merger Worth $737M - StockTitan
Acelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right Now - Insider Monkey
10 Best Short-Term Stocks to Buy Now with Rebound Potential - Insider Monkey
Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’ - BioPharma Dive
Pliant Pops Poison Pill as Concentra Threat Looms - BioSpace
Acelyrin adopts rights plan in response to Tang Capital stake By Investing.com - Investing.com Australia
Drug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investor - The Business Journals
Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy - BioSpace
Acelyrin stock in focus after poison pill (SLRN:NASDAQ) - Seeking Alpha
Acelyrin Adopts Stockholder Rights Plan; Shares Up Pre-Bell -March 13, 2025 at 08:09 am EDT - Marketscreener.com
Acelyrin adopts rights plan in response to Tang Capital stake - Investing.com India
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan - The Manila Times
Acelyrin: Potential Buyout Led By Concentra Biosciences (NASDAQ:SLRN) - Seeking Alpha
How a skin drug trial could help Peninsula biotech pull off key mergerSan Francisco Business Times - San Francisco Business Times
Is Acelyrin, Inc. (SLRN) the Best Micro Cap Stock to Buy Now? - Insider Monkey
Acelyrin, Alumis reaffirm strategic, financial rationale of proposed merger - TipRanks
New York State Common Retirement Fund Lowers Position in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
10 Best Micro Cap Stocks to Buy Now - Insider Monkey
Acelyrin falls as Acelyrin reaffirms deal commitment - MSN
Acelyrin rebuffs Concentra bid, believing Alumis option better - The Pharma Letter
Acelyrin Rejects Concentra’s Buyout Offer in Favor of Alumis Merger - BioSpace
Acelyrin To Proceed With Alumis Merger, Spurn Concentra Bid - Citeline News & Insights
Sector Update: Health Care Stocks Lower Tuesday Afternoon -March 04, 2025 at 02:01 pm EST - Marketscreener.com
Acelyrin Reaffirms Merger Deal With Alumis -March 04, 2025 at 10:13 am EST - Marketscreener.com
Acelyrin stock falls on Acelyrin deal commitment (SLRN:NASDAQ) - Seeking Alpha
Alumis Inc. Announces Merger with ACELYRIN, Inc. - TipRanks
Acelyrin says Concentra indication not expected to result in superior proposal - TipRanks
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger - The Manila Times
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger - The Manila Times
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger - The Manila Times
Acelyrin Determines Unsolicited Indication Of Interest From Concentra Biosciences Not Reasonably Expected To Result In A Superior Proposal To Planned Alumis Merger - Marketscreener.com
ACELYRIN, INC. Reaffirms Commitment to Merger with Alumis Inc., Rejects Unsolicited Proposal from Concentra Biosciences - Nasdaq
Alumis And Acelyrin Reaffirm Strategic And Financial Rationale Of Proposed Merger -March 04, 2025 at 09:06 am EST - Marketscreener.com
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not ... - Eagle-Tribune
Can This Biopharma Merger's $737M War Chest Transform Immune Disease Treatment? - StockTitan
SHAREHOLDER ALERT: Potential Recovery for Acelyrin, Inc. (SLRN) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Notifies Acelyrin, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineSLRN - ACCESS Newswire
Acelyrin Inc Stock (SLRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acelyrin Inc Stock (SLRN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Murugan Amar | Chief Legal Officer |
Mar 17 '25 |
Sale |
2.74 |
3,913 |
10,737 |
121,587 |
| Mpofu Shephard | Chief Medical Officer |
Mar 17 '25 |
Sale |
2.74 |
3,211 |
8,811 |
121,789 |
0.00%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):